Contact

Prof. Dr. Klaus Kopka

Director Institute of Radiopharmaceuticel Cancer Research
k.kopkaAthzdr.de
Phone: +49 351 260 2060

Prof. Dr. Michael Bachmann

Director Institute of Radiopharmaceuticel Cancer Research
m.bachmannAthzdr.de
Phone: +49 351 260 3170
+49 172 694 8424
+49 351 458 2101

Marita Kersten

Secretariat / Administration
Institute of Radio­pharma­ceutical Cancer Research
m.kerstenAthzdr.de
Phone: +49 351 260 3223

Partners

Vorschau-Bild
Vorschau-Bild
Vorschau-Bild
Vorschau-Bild
Vorschau-Bild

Departments of Radiopharmaceutical Cancer Research

Radionuclide Theragnostics, Dr. Hans-Jürgen PietzschDepartment of Radionuclide Theragnostics


Radioimmunology, Dr. Anja FeldmannDepartment of Radioimmunology

  • Antibody-based immunotherapeutics and diagnostics for therapy and imaging of tumors
  • Cellular immunotherapeutics for an individualized immunotherapy and diagnostics
  • Modulation of the tumor microenvironment via manipulation with regulatory T cells and checkpoint inhibitors
  • Combination of immunotherapies with other tumor therapies (e.g. external or internal radiotherapy)

Radiopharmaceutical and Chemical Biology, Prof. Dr. Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology

  • Radiotracer and Drug Development
  • Theranostic Targets and Experimental Models
  • Radiopharmacology and Cancer Imaging
  • Tissue Regeneration and Inflammation Imaging

Positron Emission Tomography, Prof. Dr. Jörg van den HoffDepartment of Positron Emission Tomography

  • Improved quantification of functional information in oncological PET
  • Quantitative perfusion imaging using functional ASL-MRI
  • Multimodal imaging and assessment of in-vivo quantification accuracy
  • Motion compensation methods for PET
  • High resolution PET image reconstruction

Translational TME Ligands, Prof. Dr. Klaus KopkaDepartment of Translational TME Ligands

  • Small molecule and peptide-based radiotracer for PET-Imaging of TME receptors
  • Radiolabeled near-infrared (NIR) fluorescence dyes for optical and radio imaging
  • Combination with theranostic approaches (e.g. endoradiotherapy and radioimmunotherapy)

Radiopharmaceuticals Production, Dr. Torsten KnießDepartment of Radiopharmaceuticals Production

  • GMP-certified Radiopharmaceuticals Production
  • Radiotracer and Radionuclides for Science

Neuroradiopharmaceuticals, Prof. Dr. Peter BrustDepartment of Neuroradiopharmaceuticals

  • Molecular imaging of adenosine signalling in cancer
  • Molecular imaging of α7 nAChR in cancer and brain diseases
  • [18F]Flubatine - a potential PET marker of early Alzheimer`s disease
  • Development of new ligands and 18F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
  • New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
  • Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
  • Development of 18F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases

Contact

Prof. Dr. Klaus Kopka

Director Institute of Radiopharmaceuticel Cancer Research
k.kopkaAthzdr.de
Phone: +49 351 260 2060

Prof. Dr. Michael Bachmann

Director Institute of Radiopharmaceuticel Cancer Research
m.bachmannAthzdr.de
Phone: +49 351 260 3170
+49 172 694 8424
+49 351 458 2101

Marita Kersten

Secretariat / Administration
Institute of Radio­pharma­ceutical Cancer Research
m.kerstenAthzdr.de
Phone: +49 351 260 3223